1309 GMT - AstraZeneca's revenue miss in oncology segment should concern investors but its long-term story seems intact, Barclays analysts say in a note. The British pharma giant posted mixed 1Q results as some of its oncology and rare disease drugs fell short of company-compiled sales consensus, the analysts say. "While we believe investors would question the oncology misses, important catalyst readouts planned for later this year and AstraZeneca being less susceptible to the ever-emerging tariff situation in the U.S., we see AstraZeneca as best positioned in our coverage," they say. Shares are down 0.3% at 104.90 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 29, 2025 09:09 ET (13:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.